Categories
Health

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is  a   biotech that has been effective vigilantly but unsuccessfully to develop a single therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular treatment, CytoDyn has cast its net far and wide both geographically and in terminology of possible indications.

CytoDyn’s inventories of leronlimab are building up, whether they’ll actually be being used is an open question.

While CYDY  happens to be dawdling, market opportunities for leronlimab as a combination treatment in the healing of multi-drug-resistant HIV are actually closing.

I am creating my fifteenth CytoDyn (OTCQB:CYDY) report on FintechZoom to celebrate the sale of my past several shares. The first CytoDyn post of mine, “CytoDyn: What to be able to Do When It’s Too Good In order to Be True?”, set away all of the following prediction:

Rather I expect it to turn into a serial disappointer. CEO Pourhassan offered such an extremely promotional image in the Uptick Newswire job interview which I came away with an inadequate opinion of the company.

Irony of irony, the bad impression of mine of the business has grown steadily, however, the disappointment hasn’t been financial. 2 decades ago CytoDyn was trading <$1.00. On 2/19/20 as I write, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that gives a > 6 bagger at the moment still disappoints? Therein sits the story; allow me to explain.

CytoDyn acquired its much storied treatment (which I shall relate to as leronlimab) returned in 2012, announced as follows:

CytoDyn Inc…. has completed the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for the therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical development mAb with demonstrated anti viral activity of HIV- infected subjects. Today’s transaction of $3.5 million transfers ownership of the expertise and also associated intellectual property coming from Progenics to CytoDyn, and approximately 25 million mg of majority drug substance…. milestone payments upon commencement of a stage III clinical trial ($1.5 zillion) and the very first new drug program approval ($5 million), and also royalty payments of five percent of net sales after commercialization.

Since that moment, CytoDyn’s leading nous, Nader Pourhassan [NP] has turned this inauspicious acquisition into a springboard for CytoDyn to purchase a sector cap > $3.5 billion. It’s done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Instead of having a pipeline with numerous therapies and many indications, it has this single treatments and a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a likely beneficial therapy of dozens of indications.

The opening banner of its on its site (below) shows an energetic company with diverse interests albeit centered on leronlimab, several illness sorts, multiple publications and multiple delivering presentations.

Could all of it be smoke cigarettes and mirrors? That is a question I’ve been asking myself with the really start of my interest in this particular business. Judging by the multiples of thousands of several commentary on listings accessible via Seeking Alpha’s CytoDyn Summary webpage, I’m much from alone in this particular question.

CytoDyn is a classic battleground, or possibly some might say cult inventory. Its adherents are fiercely shielding of the prospects of its, quick to label some bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Leave a Reply

Your email address will not be published. Required fields are marked *